Temsirolimus Plus Bortezomib Safe, Active for Relapsed/Refractory B-Cell NHL
the ONA take:
The combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe and has activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, a recent study published in the journal Cancer has shown.
For the single-arm, phase 2 trial, researchers enrolled 39 patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
The patients received bortezomib and temsirolimus weekly on days 1, 8, 15, and 22 of a 35-day cycle. This dosing scheme has previously been studied in patients with multiple myeloma.
Results showed that 7.7% of patients achieved a complete response and 23% achieved a partial response. Median progression-free survival was 4.7 months (2 months for patients with diffuse large B-cell lymphoma, 7.5 months for those with mantle cell lymphoma, and 16.5 months for those with follicular lymphoma).
Researchers found that two extensively treated patients with diffuse large B-cell lymphoma achieved a complete response. In regard to safety, there were no unexpected toxicities with the combination.
“Further studies with this combination are warranted in specific subtypes of NHL,” the authors conclude.
The combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe in B-cell non-Hodgkin lymphoma.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|